Despite advances in LDL-C control, elevated Lp(a) and severe hypertriglyceridemia (SHTG) continue to drive residual ASCVD risk. Novel RNA-based therapies, such as siRNA and ASO agents, are reshaping the treatment landscape. Dr. Michos highlights why addressing Lp(a) matters now, plus how and why clinicians can stay informed.
advertisement
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Related
videoDARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Show more- video
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Show more - video
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Show more - video
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Show more - video
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more - video
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Show more - video
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Show more - video
Highlights of the Latest Hypertension Guidelines
Show more - video
Clinical Perspective on New Therapies in Resistant Hypertension
Show more
Recommended
Details
Presenters
Related
Overview
Despite advances in LDL-C control, elevated Lp(a) and severe hypertriglyceridemia (SHTG) continue to drive residual ASCVD risk. Novel RNA-based therapies, such as siRNA and ASO agents, are reshaping the treatment landscape. Dr. Michos highlights why addressing Lp(a) matters now, plus how and why clinicians can stay informed.
Provider(s)/Educational Partner(s)
- video
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Show more - video
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Show more - video
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Show more - video
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Show more - video
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more - video
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Show more - video
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Show more - video
Highlights of the Latest Hypertension Guidelines
Show more - video
Clinical Perspective on New Therapies in Resistant Hypertension
Show more
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?